-
How Will Patient Registry Data Play a Role in Joint Clinical Assessment (JCA) for Rare Diseases Learnings From National Health Technology Assessments (HTAs)?
Sep 9, 2025, 16:22 PM -
Hospital Systemic Treatment for HepatoCarcinoma: The HOSTHECA Study
Sep 9, 2025, 16:22 PM -
Health Economic Evaluation Model for Ovarian Cancer Risk Management Through Preimplantation Genetic Testing for Monogenic Disorders (PGT-M)
Sep 9, 2025, 16:22 PM -
DARAH Project: Deploying a Datashield Federated Network in Real-World Healthcare Environments
Sep 9, 2025, 16:22 PM -
Current Status of Home-Healthcare Pilot Programs in South Korea and Policy Discussions for Institutionalization
Sep 9, 2025, 16:22 PM -
Inducing Labor in Denmark: A Descriptive Study
Sep 9, 2025, 16:22 PM -
The Soft Science in Hard Decisions: Utility of Qualitative Evidence in HTA Decisions
Sep 9, 2025, 16:22 PM -
Domain Attrition in the IWQOL Series and the Challenges of Factor-Only Item Reduction
Sep 9, 2025, 16:22 PM -
Prevalence of Migraine in India: A Meta-Analysis Based on Diagnostic Criteria and Gender Differences
Sep 9, 2025, 16:22 PM -
Real-World Treatment Patterns and Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Previously Treated With First-Line (1L) Platinum-Based Chemotherapy (PBC)
Sep 9, 2025, 16:22 PM -
A Real-World Survey of Health Inequalities as Drivers for Burden on Male Hemophilia Patients in the US, EU5, and Asia
Sep 9, 2025, 16:22 PM -
Real-World Utilization Pattern of GLP-1 Receptor Agonists in German Outpatient Care
Sep 9, 2025, 16:22 PM -
Unlocking the Value of RSV Adult Vaccination With Adjuvanted RSVpreF3 Vaccine in Germany: A Return on Investment Analysis Using an Integrated Actuarial-Macroeconomic Model
Sep 9, 2025, 16:22 PM -
Stakeholder Mapping and Policy Assessment of Rare Diseases in Southeast Asia
Sep 9, 2025, 16:22 PM -
Estimating Costs Avoided by Preventing Recurrences With a BRCA Testing Strategy in High-Risk HER2-Negative Adjuvant Breast Cancer Patients in Spain
Sep 9, 2025, 16:22 PM -
Assessment of Severity Modifiers vs. End-of-Life Criteria in Oncology
Sep 9, 2025, 16:22 PM -
Danicopan: A Dominant Option for the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) With Residual Hemolytic Anemia in Spain
Sep 9, 2025, 16:22 PM -
Estimating Life-Years and QALYs Gained From Tumor Treating Fields in Newly Diagnosed Glioblastoma: A US-Based Real-World Survival-Based Model
Sep 9, 2025, 16:22 PM -
Evaluating the Economic Impact of Worksite Physical Activity Interventions in Denmark: An Employer’s Perspective
Sep 9, 2025, 16:22 PM -
A Real-World Study on Italian Administrative Healthcare Data to Describe Patients With Chronic Obstructive Pulmonary Disease by Therapeutic Pattern and Exacerbation Rate
Sep 9, 2025, 16:22 PM
